Results For "Emalex-Biosciences"

1 News Found

Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout

News | April 30, 2026

Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout

The agreement could rise to $900 million if key commercial milestones are met

Latest Stories

BD, Suttons Creek partner to streamline combination product development

RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth

Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India

Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India

Kavinder Beniwal Chief Operational Officer, Motorica India

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics

Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings

Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.

Packaging